Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
AGEN 
Agenus Inc (AGEN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/13/2025: AGEN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -62.77% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 128.86M USD | Price to earnings Ratio 0.16 | 1Y Target Price 11.5 |
Price to earnings Ratio 0.16 | 1Y Target Price 11.5 | ||
Volume (30-day avg) 1340141 | Beta 1.43 | 52 Weeks Range 1.38 - 18.74 | Updated Date 06/15/2025 |
52 Weeks Range 1.38 - 18.74 | Updated Date 06/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 29.61 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -191.5% | Operating Margin (TTM) -55.31% |
Management Effectiveness
Return on Assets (TTM) -28.7% | Return on Equity (TTM) -1278.83% |
Valuation
Trailing PE 0.16 | Forward PE 2.78 | Enterprise Value 202414195 | Price to Sales(TTM) 1.29 |
Enterprise Value 202414195 | Price to Sales(TTM) 1.29 | ||
Enterprise Value to Revenue 2.03 | Enterprise Value to EBITDA -2.42 | Shares Outstanding 27416800 | Shares Floating 27017935 |
Shares Outstanding 27416800 | Shares Floating 27017935 | ||
Percent Insiders 1.43 | Percent Institutions 34.04 |
Analyst Ratings
Rating 3.6 | Target Price 11.5 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Agenus Inc
Company Overview
History and Background
Agenus Inc. (AGEN) is an immuno-oncology company founded in 1994, originally known as Antigenics. It focuses on developing therapies to activate the immune system to fight cancer. It has evolved from a vaccine-focused company to one developing antibody-based therapeutics.
Core Business Areas
- Antibody Discovery and Development: Agenus focuses on discovering and developing novel antibodies to target various cancer pathways.
- Cell Therapy: Development of cell therapies, including adoptive cell transfer approaches.
- Adjuvant Development: Creating adjuvants to enhance immune responses in vaccines and therapies.
- Collaboration and Licensing: Partnering with other pharmaceutical companies to advance their pipeline candidates and providing technology licensing.
Leadership and Structure
The leadership team includes Dr. Garo Armen as Chairman and CEO. The company has a typical hierarchical structure with departments for research, development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- Balstilimab: An anti-PD-1 antibody being evaluated in clinical trials, primarily for cervical cancer. Agenus entered into a license agreement with Betta Pharmaceuticals Co., Ltd. Market share data is unavailable. Competitors include Keytruda (Merck), Opdivo (Bristol Myers Squibb) and Libtayo (Regeneron).
- AGEN1777: A next-generation anti-TIGIT antibody designed to enhance anti-tumor immunity. Currently in clinical trials. Market share data is unavailable. Competitors include Roche's tiragolumab and Gilead's domvanalimab.
- QS-21 Stimulon adjuvant: An immune-stimulant used in vaccines and immunotherapies. Partnered with GSK to use in its shingles vaccine, Shingrix. Estimated to generate significant revenue stream for Agenus. Market share unavailable. Competitors include other adjuvant providers.
Market Dynamics
Industry Overview
The immuno-oncology industry is rapidly growing, driven by the success of checkpoint inhibitors and the increasing understanding of the role of the immune system in cancer. Development of novel immunotherapies remains an active area of research.
Positioning
Agenus is a smaller player in the immuno-oncology space, focusing on developing novel antibodies and adjuvants. Its competitive advantage lies in its innovative technology and strategic partnerships.
Total Addressable Market (TAM)
The global cancer immunotherapy market is expected to reach hundreds of billions of dollars in the coming years. Agenus is positioned to capture a portion of this TAM through its pipeline and partnerships, particularly in areas where current therapies are not effective.
Upturn SWOT Analysis
Strengths
- Novel antibody discovery platform
- QS-21 Stimulon adjuvant partnership with GSK
- Experienced management team
- Diverse pipeline of immuno-oncology assets
Weaknesses
- Limited financial resources compared to larger competitors
- Dependence on partnerships for revenue generation
- Clinical trial risks and regulatory hurdles
- History of operating losses
Opportunities
- Potential for breakthrough therapies in cancer treatment
- Expansion of partnerships with larger pharmaceutical companies
- Advancements in personalized medicine and immunotherapy
- Expanding clinical trials into new indications
Threats
- Competition from established immuno-oncology companies
- Failure of clinical trials
- Regulatory challenges and delays
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- MRK
- BMY
- REGN
- GSK
Competitive Landscape
Agenus faces significant competition from larger, more established pharmaceutical companies. Agenus needs to show positive trial results and secure financial funding to stay afloat.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Agenus's historical growth has been driven by partnerships and clinical trial advancements. Revenue streams are mostly dependent on milestone payments and royalties.
Future Projections: Future growth depends on successful clinical trial outcomes for its key pipeline assets and continued expansion of partnerships. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing its anti-TIGIT program, securing new partnerships, and streamlining operations to reduce costs.
Summary
Agenus is a high-risk, high-reward immuno-oncology company with an innovative technology platform. While its partnerships, particularly with GSK, provide some revenue, its financial stability relies on positive clinical trial results and further collaborations. Competition is fierce, and the company must overcome regulatory hurdles and significant development costs. Agenus needs to focus on improving its financials to be more competitive.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Company Website
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be construed as financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share figures are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Agenus Inc
Exchange NASDAQ | Headquaters Lexington, MA, United States | ||
IPO Launch date 2000-02-04 | Founder, Executive Chairman & CEO Dr. Garo H. Armen Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 316 | Website https://www.agenusbio.com |
Full time employees 316 | Website https://www.agenusbio.com | ||
Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract t; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.